News Releases

2024-12-19 15:59:46	LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and U
2024-12-12 16:14:21	LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in C
2024-11-07 16:16:46	LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regul
2024-10-29 16:17:49	LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
2024-10-25 16:19:14	LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJ
2024-10-08 16:19:55	LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025
2024-09-27 16:20:48	LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation
2024-09-10 16:21:46	Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024
2024-09-04 16:22:44	LakeShore Biopharma Announces Leadership Transitions
2024-08-15 16:23:48	LakeShore Biopharma Announces Financial Results for Fiscal Year 2024
2024-07-05 16:24:57	LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Sharehold
2024-05-24 16:26:32	YS Biopharma Announces Name Change to LakeShore Biopharma
2024-05-21 16:28:12	YS Biopharma Announces Results of Extraordinary General Meeting
2024-05-07 16:28:56	YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of
2024-04-29 16:29:46	YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid P
2024-04-19 16:30:39	YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
2024-04-18 16:31:51	YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
2024-04-16 16:32:44	YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
2024-04-09 16:33:37	YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vac
2024-04-03 16:34:55	YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility
2024-03-05 16:35:47	YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries
2024-02-22 15:52:47	YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024
2024-02-16 15:52:02	/C O R R E C T I O N -- YS Biopharma Co., Ltd./
2024-02-16 15:51:25	YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements abo
2024-02-14 15:50:54	YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder
2024-02-14 15:50:34	YS Biopharma Announces Appointment of New Directors
2024-02-12 15:49:58	YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma C
2024-02-09 15:49:18	YS Biopharma Announces US$40 Million Private Placement Financing
2024-01-22 15:48:29	YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024
2024-01-08 15:47:40	YS Biopharma Announces Changes to its Board Committees
2023-12-20 15:47:18	YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting
2023-11-14 15:46:34	Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Ta
2023-10-31 15:46:08	YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Ra
2023-10-26 15:45:34	YS Biopharma Announces Receipt of Nasdaq Notice
2023-09-26 15:45:01	YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vac
2023-09-15 15:44:20	YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infect
2023-09-05 15:43:47	YS Biopharma to Participate in Citi's 18th Annual Biopharma Conference
2023-08-24 15:43:14	YS Biopharma Announces Purchase of Shares by Company Officers
2023-08-15 15:42:27	YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024
2023-08-10 15:37:01	YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023
2023-07-26 15:35:56	YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023
2023-07-21 15:35:10	YS Biopharma to Report Financial Results for Fiscal Year 2023 on July 26, 2023
2023-06-01 15:34:32	YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA
2023-05-18 15:34:08	YS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 202
2023-05-16 15:33:33	YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in Pakistan
2023-04-18 15:32:40	YS Biopharma Announces Record Vaccine Revenues and Preliminary Financial Results for FY2023 Ended Ma
2023-03-27 15:31:48	YS Biopharma's PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Respo
2023-03-16 15:31:25	YS BIOPHARMA TO RING THE OPENING BELL AND DEBUT ON NASDAQ
2023-03-14 15:30:39	YS BIOPHARMA AND SUMMIT HEALTHCARE ANNOUNCE SHAREHOLDER APPROVAL OF BUSINESS COMBINATION
2023-02-08 15:29:43	SUMMIT HEALTHCARE ACQUISITION CORP. AND YS BIOPHARMA ANNOUNCE EFFECTIVENESS OF REGISTRATION STATEMEN
2022-11-15 15:29:16	YS Biopharma Received Qualified Person Declaration for Its PIKA COVID-19 Vaccine Facility Equivalent
2022-11-10 15:28:28	YS Biopharma Announces US FDA Clearance Of IND Application For PIKA COVID-19 vaccine
2022-09-29 15:27:58	YS BIOPHARMA TO MERGE WITH NASDAQ-LISTED SUMMIT HEALTHCARE ACQUISITION CORP.
2022-09-08 15:25:14	YishengBio Received Approvals From Philippines and UAE For Phase 2 / 3 Clinical Trials of PIKA Recom
2021-02-24 14:24:52	YishengBio Raises $130 Million in Series B Funding to Accelerate Pipeline Development and Commercial

News Releases

Contact Info